Inventor · disambiguated record
William G. Kaelin, Jr.
Also filed as: KAELIN JR WILLIAM G · KAELIN WILLIAM · KAELIN WILLIAM G · KAELIN WILLIAM G JR
16 granted patents·12 pending applications·125 citations·filing 1992–2022
92Inventor score
Files withDANA FARBER CANCER INST INC20KAELIN JR WILLIAM G3ALNYLAM PHARMACEUTICALS INC1KAELIN WILLIAM1KAELIN WILLIAM G JR1
Top patents by PatentIndex Score
28 records- 0192US6855510B2Pharmaceuticals and methods for treating hypoxia and screening methods thereforDANA FARBER CANCER INST INC·Filed 2002·Granted Feb 15, 2005·41 cites·54 claims
- 0288US6849718B2Muteins of hypoxia inducible factor alpha and methods of use thereofDANA FARBER CANCER INST INC·Filed 2002·Granted Feb 1, 2005·31 cites·4 claims
- 0385US7176345B2Transgenic animals expressing light-emitting fusion proteins and diagnostic and therapeutic methods thereforDANA FARBER CANCER INST INC·Filed 2002·Granted Feb 13, 2007·22 cites·11 claims
- 0483US7985563B2HIFαprolyl hydroxylation assayDANA FARBER CANCER INST INC·Filed 2007·Granted Jul 26, 2011·4 cites·11 claims
- 0579US8809011B2HIFα hydroxylation assayKAELIN JR WILLIAM G·Filed 2011·Granted Aug 19, 2014·3 cites·6 claims
- 0677US9193973B2Compositions and methods for increasing erythropoietin (EPO) productionKAELIN JR WILLIAM G·Filed 2011·Granted Nov 24, 2015·2 cites·27 claims
- 0776US7919274B2Light-emitting fusion proteins and diagnostic and therapeutic methods thereforDANA FARBER CANCER INST INC·Filed 2002·Granted Apr 5, 2011·5 cites·3 claims
- 0876US2022291216A1Pharmaceuticals and methods for treating hypoxia and screening methods thereforDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
- 0970US2020209239A1Pharmaceuticals and methods for treating hypoxia and screening methods thereforDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
- 1067US9766240B2Method of identifying a compound for treating a hypoxic or ischemic related disorderDANA FARBER CANCER INST INC·Filed 2014·Granted Sep 19, 2017·0 cites·11 claims
- 1167US7361463B2Muteins of hypoxia inducible factor alpha and methods of use thereofDANA FARBER CANCER INST INC·Filed 2004·Granted Apr 22, 2008·3 cites·6 claims
- 1266US10365278B2Pharmaceuticals and methods for treating hypoxia and screening methods thereforDANA FARBER CANCER INST INC·Filed 2017·Granted Jul 30, 2019·0 cites·9 claims
- 1366US2010233735A1Pharmaceuticals and methods for treating hypoxia and screening methods thereforDANA FARBER CANCER INST INC·Filed 2008·Application pending·0 cites
- 1460US7666997B2Methods of treatment using NBS-1, antibodies and proteins thereto, and uses of the antibodiesDANA FARBER CANCER INST INC·Filed 2002·Granted Feb 23, 2010·0 cites·8 claims
- 1560US2005186650A1Pharmaceuticals and methods for treating hypoxia and screening methods thereforFiled 2004·Application pending·0 cites
- 1658US2022357311A1Methods and compositions for the positive selection of protein destabilizersDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 1758US2004248233A1Pharmaceuticals and methods for treating hypoxia and screening methods thereforFiled 2004·Application pending·0 cites
- 1856US10233452B2Compositions and methods for increasing erythropoietin (EPO) productionALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Mar 19, 2019·0 cites·25 claims
- 1956US6451979B1Methods of treatment using NBS-1, antibodies and proteins thereto, and uses of the antibodiesDANA FARBER CANCER INST INC·Filed 1998·Granted Sep 17, 2002·7 cites·10 claims
- 2052US2010016434A1Inhibitors of Egln3 Activity for the Treatment of Neurodegenerative DisordersKAELIN JR WILLIAM G·Filed 2006·Application pending·0 cites
- 2152US2011275697A1Regulation of cyclin dDANA FARBER CANCER INST INC·Filed 2009·Application pending·0 cites
- 2250US11340216B2Methods and compositions for the positive selection of protein destabilizersDANA FARBER CANCER INST INC·Filed 2017·Granted May 24, 2022·0 cites·18 claims
- 2346US5759803ARecombinant retinoblastoma-associated protein 1 (E2F-1) polypeptides and cDNADANA FARBER CANCER INST INC·Filed 1992·Granted Jun 2, 1998·7 cites·42 claims
- 2446US2006206950A1In vivo imaging of e2f-fegulated bioluminescent proteinsKAELIN WILLIAM G JR·Filed 2003·Application pending·0 cites
- 2544US2006252763A1Treatment of von hippel lindau diseaseKAELIN WILLIAM·Filed 2003·Application pending·0 cites
- 2638US2017306385A1Methods for discovering therapeutics that alter the stability of target proteinsDANA FARBER CANCER INST INC·Filed 2015·Application pending·0 cites
- 2738US2017292959A1Plasmids comprising internal ribosomal entry sites and uses thereofDANA FARBER CANCER INST INC·Filed 2015·Application pending·0 cites
- 2827US5981723ARetinoblastoma-associated protein 1 CDNADANA FARBER CANCER INST INC·Filed 1995·Granted Nov 9, 1999·0 cites·1 claims
Join the waitlist — get patent alerts
Get an alert when William G. Kaelin, Jr. files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →